Aristotle Capital Management Trimmed Total S A (TOT) Position By $367,950, Crispr Therapeutics AG (CRSP) Shorts Up By 10.17%

June 21, 2017 - By Peter Erickson

Crispr Therapeutics AG (NASDAQ:CRSP) had an increase of 10.17% in short interest. CRSP’s SI was 501,700 shares in June as released by FINRA. Its up 10.17% from 455,400 shares previously. With 83,700 avg volume, 6 days are for Crispr Therapeutics AG (NASDAQ:CRSP)’s short sellers to cover CRSP’s short positions. The SI to Crispr Therapeutics AG’s float is 6.16%. The stock increased 1.08% or $0.16 on June 21, reaching $15.04. About 81,646 shares traded. Crispr Therapeutics AG (NASDAQ:CRSP) has 0.00% since June 21, 2016 and is . It has underperformed by 16.70% the S&P500.

Aristotle Capital Management Llc decreased Total S A (TOT) stake by 4.6% reported in 2016Q4 SEC filing. Aristotle Capital Management Llc sold 7,359 shares as Total S A (TOT)’s stock rose 7.42%. The Aristotle Capital Management Llc holds 152,482 shares with $7.77M value, down from 159,841 last quarter. Total S A now has $121.34B valuation. The stock decreased 0.56% or $0.28 on June 21, reaching $49.46. About 2.08 million shares traded or 12.43% up from the average. Total SA (ADR) (NYSE:TOT) has risen 13.67% since June 21, 2016 and is uptrending. It has underperformed by 3.03% the S&P500.

Among 5 analysts covering CRISPR Therapeutics (NASDAQ:CRSP), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. CRISPR Therapeutics had 5 analyst reports since November 14, 2016 according to SRatingsIntel. The rating was initiated by Citigroup with “Neutral” on Tuesday, November 15. The firm has “Overweight” rating by Barclays Capital given on Monday, November 14. On Monday, November 14 the stock rating was initiated by Guggenheim with “Buy”. Piper Jaffray initiated the shares of CRSP in report on Monday, November 14 with “Overweight” rating.

Crispr Therapeutics AG is a Switzerland gene-editing company. The company has market cap of $605.22 million. The Firm focuses on the development of transformative gene medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats /Cas9 gene-editing platform. It has a 281.49 P/E ratio. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Among 20 analysts covering Total SA (NYSE:TOT), 12 have Buy rating, 0 Sell and 8 Hold. Therefore 60% are positive. Total SA had 23 analyst reports since August 24, 2015 according to SRatingsIntel. Barclays Capital upgraded Total SA (ADR) (NYSE:TOT) on Thursday, August 4 to “Overweight” rating. As per Thursday, December 1, the company rating was upgraded by Independent Research. The firm has “Hold” rating by Deutsche Bank given on Tuesday, December 6. The firm earned “Neutral” rating on Friday, July 15 by Bank of America. The rating was downgraded by Goldman Sachs to “Buy” on Friday, March 11. The stock of Total SA (ADR) (NYSE:TOT) earned “Sector Outperform” rating by Howard Weil on Thursday, October 8. The stock of Total SA (ADR) (NYSE:TOT) has “Accumulate” rating given on Monday, September 21 by Tudor Pickering. Societe Generale upgraded the shares of TOT in report on Tuesday, September 22 to “Buy” rating. The stock of Total SA (ADR) (NYSE:TOT) earned “Neutral” rating by Credit Suisse on Wednesday, November 30. The firm has “Neutral” rating given on Wednesday, November 2 by JP Morgan.